Clinical trial

Comparing the Acute Effects of Tiotropium Handihaler With Tiotropium Respimat on the Ventilation Distribution in COPD Patients

Name
Pro00112737
Description
The purpose of this study is to determine if tiotropium Respimat will result in better ventilation distribution of the lung in COPD participants quantified by hyperpolarized XeMRI. This study is designed to simulate the real-life clinical setting where patients receive one-time instruction on the inhaler use.
Trial arms
Trial start
2023-05-01
Estimated PCD
2024-05-01
Trial end
2024-05-01
Status
Withdrawn
Phase
Early phase I
Treatment
tiotropium bromide inhalation powder (Spiriva HandiHaler)
Spiriva HandiHaler is a COPD medication that is available for use.
Arms:
Tiotropium bromide inhalation powder (Spiriva HandiHaler)
tiotropium bromide (Spiriva Respimat)
Spiriva Respimat is a COPD medication that is available for use.
Arms:
Tiotropium bromide (Spiriva Respimat)
Hyperpolarized 129XeMRI
Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved
Arms:
Tiotropium bromide (Spiriva Respimat), Tiotropium bromide inhalation powder (Spiriva HandiHaler)
Primary endpoint
Assess the change in ventilation distribution parameters by 129Xe MRI in patient while taking Spiriva HandiHaler
1 visit, up to 4 hours
Assess the change in ventilation distribution parameters by 129Xe MRI in patient while taking patient while taking Spiriva Respimat
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva HandiHaler
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat
1 visit, up to 4 hours
Assess the changes in Pre- and Post-Spirometry procedure while on Spiriva Respimat
1 visit, up to 4 hours
Eligibility criteria
Inclusion Criteria: 1. Outpatients of either gender, age \> 40. 2. Willing and able to give informed consent and adhere to visit/protocol schedules. (Consent must be given before any study procedures are performed) 3. Women of childbearing potential must have a negative urine pregnancy test. This will be confirmed before participation in this investigational protocol. 4. Clinical diagnosis of COPD confirmed by post-bronchodilator spirometry demonstrating FEV1/FVC \< 0.70 in all GOLD stages (http://www.goldcopd.org/). 5. Patients who are tiotropium naïve or whose tiotropium can be withheld for 2 weeks before screening visit/visit 1 Exclusion Criteria: 6. Upper respiratory tract infection within 6 weeks (in this case, we will re-screen the patient after 6 weeks) 7. 24/7 oxygen use 8. Previous history of pneumothorax 9. Evidence of interstitial, occupational or chronic infectious lung disease by imaging studies 10. For women of child bearing potential, positive pregnancy test. 11. Major chronic illnesses which in the judgement of the study physician would interfere with participation in the study 12. History of claustrophobia
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2023-06-15

1 organization

3 products

1 indication

Organization
Duke University